MDT logo

MDT

Medtronic plcNYSEHealthcare
$86.63+0.66%OpenMarket Cap: $111.22B

As of 2026-04-06

Valuation

View Details

P/E (TTM)

24.11

PEG

2.90

P/B

2.27

P/S

3.13

EV/EBITDA

14.77

DCF Value

$173.68

FCF Yield

4.9%

Div Yield

3.3%

Margins & Returns

Gross Margin

61.9%

Operating Margin

17.9%

Net Margin

13.0%

ROE

9.5%

ROA

11.8%

ROIC

6.4%

Financials

View All
PeriodRevenueNet IncomeEPS
Q3 2026$9.02B$1.14B$0.89
Q2 2026$8.96B$1.37B$1.07
Q1 2026$8.58B$1.04B$0.81
Q4 2025$8.93B$1.06B$0.82

Analyst Ratings

View All
BarclaysOverweight
2026-04-01
Piper SandlerNeutral
2026-04-01
NeedhamBuy
2026-03-26
BarclaysOverweight
2026-02-18
BairdNeutral
2026-02-18

Trading Activity

Insider Trades

View All
Pieton Thierryofficer: EVP & Chief Financial Officer
SellThu Mar 05
KIIL HARRY SKIPofficer: EVP & President Cardiovascular
SellThu Feb 26
KIIL HARRY SKIPofficer: EVP & President Cardiovascular
SellThu Feb 26
KIIL HARRY SKIPofficer: EVP & President Cardiovascular
SellThu Feb 26
KIIL HARRY SKIPofficer: EVP & President Cardiovascular
SellThu Feb 26

Company Info

Sector

Healthcare

Industry

Country

IE

Exchange

NYSE

Beta

0.76

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Peers